These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32574384)

  • 21. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
    Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
    Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
    Syrjänen KJ
    Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway.
    Feiring B; Laake I; Christiansen IK; Hansen M; Stålcrantz J; Ambur OH; Magnus P; Jonassen CM; Trogstad L
    J Infect Dis; 2018 Nov; 218(12):1900-1910. PubMed ID: 30010913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied.
    Vänskä S; Luostarinen T; Baussano I; Apter D; Eriksson T; Natunen K; Nieminen P; Paavonen J; Pimenoff VN; Pukkala E; Söderlund-Strand A; Dubin G; Garnett G; Dillner J; Lehtinen M
    J Infect Dis; 2020 Aug; 222(6):948-956. PubMed ID: 32161969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings.
    Donkoh ET; Dassah ET; Owusu-Dabo E
    BMC Womens Health; 2022 Jun; 22(1):234. PubMed ID: 35710373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women.
    Ermel AC; Shew ML; Weaver BA; Qadadri B; Denski C; Tu W; Tong Y; Fortenberry JD; Brown DR
    Sex Transm Infect; 2014 Feb; 90(1):64-9. PubMed ID: 24031030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in HPV Seroprevalence from an Unvaccinated toward a Girls-Only Vaccinated Population in the Netherlands.
    Pasmans H; Hoes J; Tymchenko L; de Melker HE; van der Klis FRM
    Cancer Epidemiol Biomarkers Prev; 2020 Nov; 29(11):2243-2254. PubMed ID: 32856612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening.
    Shilling H; Murray G; Brotherton JML; Hawkes D; Saville M; Sivertsen T; Chambers I; Roberts J; Farnsworth A; Garland SM; Hocking JS; Kaldor J; Guy R; Atchison S; Costa AM; Molano M; Machalek DA
    Vaccine; 2020 Jan; 38(5):1186-1193. PubMed ID: 31767467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain.
    Purriños-Hermida MJ; Santiago-Pérez MI; Treviño M; Dopazo R; Cañizares A; Bonacho I; Trigo M; Fernández ME; Cid A; Gómez D; Ordóñez P; Coira A; Armada MJ; Porto M; Perez S; Malvar-Pintos A;
    PLoS One; 2018; 13(8):e0201653. PubMed ID: 30075010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination.
    Lehtinen T; Söderlund-Strand A; Petäjä T; Eriksson T; Jokiranta S; Natunen K; Dillner J; Lehtinen M
    J Infect Dis; 2017 Nov; 216(8):966-968. PubMed ID: 28968844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
    Regan DG; Philp DJ; Hocking JS; Law MG
    Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preterm birth rate after bivalent HPV vaccination: Registry-based follow-up of a randomized clinical trial.
    Kalliala I; Eriksson T; Aro K; Hokkanen M; Lehtinen M; Gissler M; Nieminen P
    Prev Med; 2021 May; 146():106473. PubMed ID: 33639181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study.
    Donken R; Tami A; Knol MJ; Lubbers K; van der Sande MAB; Nijman HW; Daemen T; Weijmar Schultz WCM; de Melker HE
    BMC Public Health; 2018 Jul; 18(1):837. PubMed ID: 29976170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent Infection With Multiple Human Papillomavirus Types Among Unvaccinated and Vaccinated 17-Year-Old Norwegian Girls.
    Laake I; Feiring B; Jonassen CM; Pettersson JHO; Frengen TG; Kirkeleite IØ; Trogstad L
    J Infect Dis; 2022 Sep; 226(4):625-633. PubMed ID: 33205203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
    Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
    Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of Human Papillomavirus in Self-Collected Cervicovaginal Swabs in Young Women in the United States Between 2003 and 2012.
    Tarney CM; Klaric J; Beltran T; Pagan M; Han J
    Obstet Gynecol; 2016 Dec; 128(6):1241-1247. PubMed ID: 27824760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.